MEDTRONIC BAKKEN RESEARCH CENTER B.V.

Their core work

Medtronic Bakken Research Center is the European R&D hub of Medtronic, the world's largest medical device company. Based in Maastricht, they focus on developing advanced cardiovascular monitoring and treatment technologies, including silicon photonics-based diagnostic sensors, computational cardiac modeling tools, and implantable devices. Their H2020 participation centers on translating academic research into manufacturable medical products — bridging the gap between laboratory prototypes and clinical-grade devices for cardiovascular disease detection, cardiac rhythm management, and patient-specific treatment planning.

What they specialise in

How they've shifted over time

In their early H2020 period (2015–2017), Medtronic focused on foundational sensor technologies — laser interferometry, integrated photonics, and silicon photonics for cardiovascular disease detection — alongside adaptive electronics for cardiorespiratory conditions. By 2020, their focus shifted decisively toward clinical translation: computational cardiac modeling, patient-specific treatment planning, risk stratification, and making photonic sensors manufacturable at scale. The progression shows a clear pipeline from "can we build the sensor?" to "can we deploy it clinically and industrially?"

Medtronic is moving from research-stage photonic sensors toward production-ready, clinically validated cardiovascular monitoring devices — expect future interest in regulatory pathways, large-scale manufacturing, and real-world clinical data.

How they like to work

Medtronic participates exclusively as a consortium partner, never as coordinator — consistent with a large industrial company contributing domain expertise and industrialization capabilities rather than managing academic-heavy research projects. With 90 unique partners across 16 countries, they maintain a broad and non-repetitive network, engaging with different research groups per project. This suggests they are selective collaborators who join consortia where they can contribute specific industrial know-how (device design, manufacturing scale-up, clinical requirements) rather than building long-term dependent partnerships.

Medtronic has collaborated with 90 distinct partners across 16 countries, indicating wide European reach without geographic concentration. Their network spans universities, research institutes, and medical device manufacturers — typical of a large industrial partner that different consortia seek out for industrialization expertise.

What sets them apart

Medtronic brings something rare to H2020 consortia: the industrial endpoint. While universities and research institutes develop prototypes, Medtronic contributes real-world constraints — manufacturability, clinical requirements, regulatory awareness, and scale-up pathways. For any consortium working on cardiovascular sensors, cardiac modeling, or implantable devices, having Medtronic as a partner signals that the project has a credible path from lab bench to patient bedside. Few other H2020 participants combine deep photonics expertise with global medical device manufacturing capability.

Highlights from their portfolio

• InSiDe
  Largest single grant (EUR 1M+) and represents the maturation of their silicon photonics work — explicitly targeting manufacturability and screening-scale deployment for cardiovascular monitoring.
• REPAIR
  A strategic departure into polymeric artificial muscles for cardiac repair — signals Medtronic's exploration of next-generation implantable therapies beyond electronics and sensors.
• CARDIS
  The origin project for their silicon photonics CVD detection line, which they continued to develop through InSiDe five years later — demonstrating sustained strategic commitment.